CLINICAL_TRIALS
trial_result
· 2025-06-26
Clinical Trial Update: A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]
Summary
Phase 2 safety and tolerability study of ILB in patients with amyotrophic lateral sclerosis has been terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Birmingham | Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-06-26